Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, com-prising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecut-ive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a dis-ease or condition associated with neuronal or synaptic loss according to the disclosed regimens.
